Pertussis Vaccine Market
Report ID: SQMIG35I3158
Report ID: SQMIG35I3158
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I3158 |
Region:
Global |
Published Date: July, 2026
Pages:
157
|Tables:
122
|Figures:
77
Global Pertussis Vaccine Market size was valued at USD 5.07 Billion in 2024 and is poised to grow from USD 5.26 Billion in 2025 to USD 7.09 Billion by 2033, growing at a CAGR of 3.8% during the forecast period (2026-2033).
The major driver that is expected to propel the pertussis vaccine market trends to expand is the regulatory harmonization across economies. Manufacturers will benefit from faster time-to-market, lower development costs and increased investment in candidates as agencies such as the US food and drug administration and the European medicines agency are streamlining approval pathways for acellular formulations. An example of this dynamic is a European biotech partnering with a Southeast Asian vaccine manufacturer to co-develop an aP vaccine for infant schedules in emerging markets. The partnership not only opens the door to at-risk populations, but generates revenue flows that build resilience and stimulate R&D.
How is AI Driving the Development of Next‑Generation Pertussis Vaccines?
Artificial intelligence is transforming the design of pertussis vaccine market growth, allowing scientists to rapidly identify protective antigens, optimize combinations of adjuvants and make manufacturing processes more efficient. Machine learning algorithms analyze pathogen genomes and immune response data to predict epitopes that elicit stronger immunity. Parallel driven simulation reduces batch variability, reducing development cycles and costs. The capabilities are aligned with a growing market as health agencies look for more effective formulations for addressing increasing case numbers. Early adopters are seeing faster pre-clinical testing and quicker routes to regulatory approval, making candidates attractive to manufacturers and investors. AI also helps with safety monitoring, to detect adverse signals.
AI-driven antigen selection was integrated into UNICEF’s hexavalent vaccine launched in June 2023, cutting its development time and improving supply chain efficiency, thereby boosting market growth and increasing access to modern pertussis immunisation. The rollout illustrated how data-driven design can accelerate clinical phases and decrease production costs, spurring other manufactures to adopt similar AI platforms.
Market snapshot - (2026-2033)
Global Market Size
USD 5.07 Billion
Largest Segment
Combination Vaccines (including Pertussis antigen)
Fastest Growth
Combination Vaccines (including Pertussis antigen)
Growth Rate
3.8% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global pertussis vaccine market is segmented by product type, vaccine type, application, end user and region. Based on product type, the market is segmented into DTaP (diphtheria, tetanus, acellular pertussis), Tdap (tetanus, diphtheria, pertussis (adult booster)), whole-cell pertussis vaccines (wP) and combination vaccines (including pertussis antigen). Based on vaccine type, the market is segmented into acellular pertussis (aP) and whole-cell pertussis (wP). Based on application, the market is segmented into pediatric immunization, adolescent booster, adult booster and maternal immunization. Based on end user, the market is segmented into hospitals & clinics, government immunization programs and private healthcare facilities. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
The DTaP segment continues to dominate as the key immunization schedule for infants, offering combined protection against diphtheria, tetanus and acellular pertussis. Its long history of use in clinical practice, its safety profile and its inclusion in national childhood vaccination programs generate a steady demand. Producers profit from the existing production lines and economies of scale that reinforce market leadership and drive continuous supply chain optimization. This entrenched position also fuels continual clinical research and incremental formulation improvements, further solidifying its market foothold.
The Tdap segment sees the highest growth momentum as recommendations for adult boosters expand with increased awareness of waning immunity in older populations. The uptake of the vaccine is being driven by increased outpatient vaccination campaigns and employer driven health initiatives with manufacturers investing in enhanced formulations and distribution networks that expedite market expansion.
The maternal immunization component is important as it provides a strategic opportunity to protect the newborn prior to birth, in line with public health goals to reduce infant pertussis mortality. It is timed to coincide with regular antenatal visits ensuring high coverage among pregnant women. It has proven to be safe and has the benefit of passive antibody transfer, which clinicians appreciate. Health authorities are keen to include it in immunization schedules, and demand remains robust. This solidified acceptance also leads to additional clinical trials testing broader maternal benefits, further boosting its market position.
Meanwhile, combination vaccines segment emerges as the key high growth area, with manufacturers combining pertussis antigens with other pediatric immunizations to simplify schedules. This consolidation reduces the frequency of appointments, is attractive to caregivers and is consistent with health system efficiency drives. These more comprehensive product portfolios attract new entrants and spur investment, speeding up the overall market expansion.
To get detailed segments analysis, Request a Free Sample Report
North America global health leadership is sustained by combining a mature health infrastructure, forward-looking public health approaches and a vibrant innovation ecosystem. Population is covered by extensive immunization programs backed by well funded government initiatives. Close collaboration between academia, biotech companies and key pharmaceutical players accelerates product development and regulatory approval. High provider engagement and a sophisticated distribution network ensure reliable vaccine availability. Demand is bolstered by public confidence in vaccine safety, and the presence of integrated payer systems facilitates reimbursement, both of which contribute to a robust market environment. The area also benefits from a strong post-marketing surveillance programme which builds confidence among clinicians and caregivers. Continued investment in digital health platforms enhances the ability to track immunization status and helps facilitate timely booster administration. These elements come together to form a cohesive ecosystem that supports North America’s dominance in the global pertussis vaccine share landscape.
Pertussis vaccine market outlook in the United States is characterized by a dynamic interplay of innovative manufacturers and extensive public‑private partnerships. Broad immunization schedules are reinforced by strong payer networks and sophisticated electronic health record systems that promote high provider compliance. Continuous research collaborations accelerate next‑generation vaccine development, while robust safety monitoring bolsters public trust. These factors collectively ensure sustained market vitality and wide accessibility across diverse population segments throughout the nation.
Pertussis vaccine market forecast in Canada benefits from a universal health framework that emphasizes equitable access and coordinated provincial immunization plans. Strong collaboration between public health agencies and licensed manufacturers ensures consistent supply and high coverage rates. Emphasis on vaccine safety and transparent communication reinforces public confidence, while robust pharmacovigilance supports ongoing trust. These systemic strengths foster a stable market environment that reliably meets the needs of the entire population across Canada.
The growth of Europe’s pertussis vaccine market is being propelled by harmonized regulations that streamline product approvals across member states, spurring manufacturers to broaden their reach. Coordinated public health funding support ensures comprehensive national immunization programmes that drive consistent uptake and maintain high coverage. Collaborative research projects between leading academic centers and biotech companies are driving innovation, especially in the areas of combination vaccines and new adjuvants. Demand is reinforced by growing public awareness of respiratory disease prevention and strong health-care provider networks. Policy incentives that reward preventive health interventions also fuel activity in the market. Reimbursement schemes that are consistent with evidence-based guidelines ensure affordability, and integrated digital registries improve tracking of immunization status and booster compliance. Taken together, these dynamics position Europe as a growing and rapidly growing hub of pertussis vaccine activity.
Pertussis vaccine market regional outlook in Germany benefits from a robust pharmaceutical sector and extensive government investment in preventive health. Centralized insurance structures simplify reimbursement, fostering broad accessibility. Strong clinical research infrastructure supports ongoing evaluation of vaccine efficacy and safety, reinforcing confidence among clinicians. Coordination between federal health agencies and regional health authorities ensures consistent implementation of immunization schedules, while public health campaigns sustain high public awareness. These factors combine to maintain Germany’s dominant position within the European landscape.
Pertussis vaccine market regional forecast in the United Kingdom is accelerated by proactive NHS policies that prioritize early childhood and adolescent immunization. Rapid adoption of combination formulations simplifies delivery and improves adherence. Strong collaboration between public health bodies and research institutions fosters continuous improvement of vaccine strategies. Public education initiatives combined with transparent safety communication enhance confidence, while digital health records facilitate real‑time monitoring of coverage. These elements collectively drive the fastest growing momentum within Europe.
Pertussis vaccine industry in France is emerging amidst increasing focus on maternal and adult immunization strategies. Government health agencies are expanding recommendations to cover higher risk groups, encouraging broader vaccine utilization. Growing biotech activity within the country contributes to diversified product pipelines and collaborative clinical trials. Public health campaigns that emphasize the benefits of protection for newborns and caregivers are strengthening acceptance. These developments collectively nurture an expanding market presence.
Asia Pacific is getting stronger through government commitment, growing immunization infrastructure, and rapid technological advancement. Policy frameworks prioritizing preventive care are enabling increased inclusion of pertussis vaccines in the routine schedules of national health programs in the region. Investment in local biotechnology capabilities speeds up region-specific formulation development. Strategic alliances with global manufacturers increase supply reliability. Demand is fuelled by increased public awareness of the dangers of respiratory disease and better access to urban and developing markets. Efficient coverage monitoring through enhanced surveillance systems and digital health tools instills confidence between stakeholders. Together these dynamics enhance Asia Pacific’s role as a key player in the global pertussis vaccine ecosystem.
Pertussis vaccine market analysis in Japan is anchored by rigorous vaccine safety standards and a well‑established national immunization schedule. Strong public trust, reinforced by transparent communication from health authorities, ensures high acceptance. Domestic manufacturers leverage advanced biotech expertise to produce high‑quality formulations, often in collaboration with international partners. Integrated electronic health records support precise tracking of immunization milestones, while continuous post‑marketing surveillance sustains confidence. These attributes preserve Japan’s influential position in the regional market.
Pertussis vaccine market penetration in South Korea is propelled by aggressive government policies that endorse domestic vaccine development and fast‑track regulatory pathways. A strong biotech sector focuses on innovative formulations and localized production, reducing reliance on imports. Public health campaigns emphasize the importance of early childhood protection, driving widespread acceptance. Integration of vaccination records into national health information systems enables efficient monitoring and booster compliance. These coordinated efforts reinforce South Korea’s rapidly strengthening market presence within the Asia Pacific region.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Rising Awareness of Pertussis Risks
Government Investment in Immunization Programs
Vaccine Hesitancy Among Caregivers
Limited Cold Chain Infrastructure
Request Free Customization of this report to help us to meet your business objectives.
The competitive landscape of the global pertussis vaccine market is characterized by established vaccine manufacturers strengthening their portfolios through research collaborations, next-generation combination vaccine development, manufacturing capacity expansion, and regulatory approvals. Companies are investing in improved acellular and whole-cell pertussis vaccines, maternal immunization strategies, and innovative vaccine technologies to enhance long-term immunity and broaden global access. Strategic partnerships with public health organizations, government immunization programs, and biotechnology companies continue to support clinical development, supply chain resilience, and expanded vaccination coverage across both developed and emerging markets.
Top Player’s Company Profile
Recent Developments in the Pertussis Vaccine Market
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. As per SkyQuest analysis, the global pertussis vaccine market is growing. The major driver of the market is the growing awareness of the risks of pertussis, which drives demand for safe infant vaccines. Government investment in immunization programs provides a steady stream of funding and expands access. Another driver is the rapid growth of adult immunisation programmes which are adding booster doses for the elderly and adolescents and broadening the market. The DTaP segment still dominates the product space as it has established itself in infant schedules and North America dominates the market with strong health infrastructure and high public confidence. But vaccine hesitancy among caregivers and limited cold-chain capacity in low resource areas are notable restraints.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 5.07 Billion |
| Market size value in 2033 | USD 7.09 Billion |
| Growth Rate | 3.8% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Pertussis Vaccine Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Pertussis Vaccine Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Pertussis Vaccine Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Pertussis Vaccine Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Pertussis Vaccine Market size was valued at USD 5.07 Billion in 2024 and is poised to grow from USD 5.26 Billion in 2025 to USD 7.09 Billion by 2033, growing at a CAGR of 3.8% during the forecast period (2026-2033).
ILiAD Biotechnologies secured a $115 million Series B to advance its intranasal pertussis vaccine BPZE1 into Phase III, illustrating how sizable financing fuels competitive pressure. The company’s partnership with major vaccine distributors and its acquisition of a niche adjuvant platform underscore a trend where firms leverage M&A and strategic alliances to accelerate pipeline progression and differentiate technology in a crowded market. 'Pfizer Inc.', 'Merck & Co. Inc.', 'GlaxoSmithKline plc', 'Sanofi Pasteur SA', 'CSL Limited', 'Serum Institute of India Pvt. Ltd.', 'Biological E. Limited', 'Bharat Biotech International Ltd.', 'Panacea Biotec Limited', 'PT Bio Farma', 'Walvax Biotechnology Co. Ltd.', 'Hualan Biological Engineering Inc.', 'Shenzhen Kangtai Biological Products', 'Wuhan Institute of Biological Products', 'Chongqing Zhifei Biological Products', 'Mitsubishi Tanabe Pharma', 'Emergent BioSolutions Inc.', 'Bavarian Nordic A/S', 'BioNTech SE', 'Valneva SE'
Public health campaigns and media coverage increasingly highlight the severe complications of pertussis, especially in newborns, prompting parents and healthcare providers to prioritize vaccination. This heightened consciousness drives demand for safe and effective pertussis vaccines, encouraging manufacturers to expand production capacity and innovate formulations. Consequently, market participants experience stronger sales momentum, and the broader immunization ecosystem benefits from improved acceptance, reinforcing a positive feedback loop that sustains market expansion across diverse regions, fostering broader public health impact and supporting long-term disease control strategies.
Enhanced Adult Immunization Programs: Governments worldwide are expanding immunization schedules to include pertussis boosters for adolescents and adults, recognizing the disease’s resurgence in older age groups. These program extensions are driven by epidemiological studies showing waning immunity and a rising burden of severe cases in pregnant women and the elderly. By integrating pertussis vaccination into routine adult health visits and workplace health initiatives, public health agencies aim to close immunity gaps, improve herd protection, and stimulate demand for next‑generation vaccine formulations across global markets.
Why does North America Dominate the Global Pertussis Vaccine Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
